At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
PF-07328948 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, 4-PERIOD, CROSSOVER, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING ORAL DOSES OF PF-07328948 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS
In Brief
A Phase 1 clinical trial evaluating PF-07328948 and Placebo for Healthy. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This study is the first clinical study with PF-07328948. The safety, tolerability, and plasma pharmacokinetics and pharmacodynamics of PF-07328948 after administration of escalating, single, oral doses will be evaluated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartOct 2022
First PostedDec 2022
Primary CompletionMay 2023
TodayJul 2026
First PostedDec 16, 2022
Enrollment StartOct 17, 2022
Primary CompletionMay 3, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.5 years ago
Interventions
PF-07328948drug
investigational drug administered orally
Placebodrug
Placebo matching active drug administered orally